2002
DOI: 10.1016/s0006-8993(02)02280-1
|View full text |Cite
|
Sign up to set email alerts
|

Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein120

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
33
0

Year Published

2005
2005
2020
2020

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 51 publications
(35 citation statements)
references
References 53 publications
2
33
0
Order By: Relevance
“…During HIV-1 infection, cells can release specific viral products (82,107,113), which may induce apoptosis in bystander cells. In CNS-based cells, it has been shown that HIV-1 infection can lead to the production and release of proinflammatory cytokines (9,26,83,114), which are neurotoxic. It is believed that induction of apoptosis in the CNS occurs through the direct cytopathic effects of viral proteins and/or indirectly via the release of soluble cellular factors (35).…”
Section: Discussionmentioning
confidence: 99%
“…During HIV-1 infection, cells can release specific viral products (82,107,113), which may induce apoptosis in bystander cells. In CNS-based cells, it has been shown that HIV-1 infection can lead to the production and release of proinflammatory cytokines (9,26,83,114), which are neurotoxic. It is believed that induction of apoptosis in the CNS occurs through the direct cytopathic effects of viral proteins and/or indirectly via the release of soluble cellular factors (35).…”
Section: Discussionmentioning
confidence: 99%
“…RT-PCR, ELISA, and biological assays have also demonstrated IL-1β levels are elevated in HIVinfected macrophage/astroglia cocultures (Genis et al 1992;Epstein and Gendelman 1993). Moreover, the application of HIV-1 Tat protein to rat microglial cultures (Nicolini et al 2001) and the intracerebroventricular injection of HIV-1 envelope protein gp120 into rats (Barak et al 2002) have both been shown to stimulate IL-1β production. Notably, the behavioral abnormalities associated with gp120 injections were attenuated with IL-1 antagonist pretreatment.…”
Section: Interleukin-1βmentioning
confidence: 97%
“…[17][18][19][20] Moreover, antagonism (or genetic deletion) of cytokine activity has been found to ameliorate or reverse various symptoms of sickness behavior in cytokine or immune-challenged laboratory animals. 17,19,[21][22][23][24][25][26][27][28][29][30][31] Given the relationship among glucocorticoids, proinflammatory cytokines and behavior, we hypothesized that virally (MCMV)-infected mice rendered glucocorticoid deficient by ADX would exhibit exaggerated proinflammatory cytokine release accompanied by evidence of increased behavioral change as assessed by open-field behavior. Behavioral observation of mice in an open field is a standard paradigm for the study of locomotor activity and exploration.…”
Section: Introductionmentioning
confidence: 99%
“…32,33 Moreover, open-field behavior has been shown to be altered in cytokine-treated and infected animals as well as animals with autoimmune disease. 21,28,[34][35][36][37][38][39][40][41][42] In addition, since TNF-alpha has been demonstrated to mediate MCMV-induced consequences on survival, we examined the possibility that TNF-alpha might also contribute to behavioral alterations in MCMV-infected animals. To abrogate TNF-alpha activity, TNF-alpha receptor 1 (TNFRp55) knockout (TNF-R1-KO) mice were employed.…”
Section: Introductionmentioning
confidence: 99%